Genomic Medicine At An Inflection Point

The next chapter of genomic medicine is taking shape through two connected shifts: growing investment in in vivo therapies and continued refinement of ex vivo manufacturing. In vivo approaches hold the potential to reach more patients through scalable treatment models, while shorter ex vivo processes aim to reduce timelines and strengthen manufacturing consistency. Understanding how these strategies compare is becoming essential as developers make decisions about therapeutic design, production, and delivery.

Examine the technical challenges, strategic tradeoffs, and development priorities influencing both pathways, along with the key turning points that will determine how genomic medicines advance from promising science to accessible treatments.